Register for our free email digests:
Latest From Astellas Institute for Regenerative Medicine
Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.
Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.
Chugai is taking concrete steps into the burgeoning regenerative medicine sector in Japan through a new clinical and commercial alliance with a domestic venture for a therapy for knee cartilage disorders.
Mylan adds more than 900 over-the-counter and generic products to its portfolio with the $9.9bn acquisition of Meda. Astellas finalizes the pursuit of Ocata which it began last November.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- IntraPace Inc.
- Senior Management
Chuck Brynelsen, CEO
Bart Bandy, Chief Commercial Officer
Gary Castro, VP, Fin. & Admin.
Vince Kapral, Senior Dir., R&D
- Contact Info
Phone: (650) 316-4070
967 N. Shoreline Blvd.
Mountain View, CA 94043
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.